John B. Buse, MD, PhD: Around 2005, there were some emerging studies that suggested potential cardiovascular risks with certain diabetes medications. And this resulted in a great deal of additional focus in the lay media, in the professional press, and eventually at the Food and Drug Administration. In 2008, there was guidance that for a drug to be approved to be marketed for the treatment of diabetes in the United States, before approval, you had to exclude a high cardiovascular risk of the drug. Specifically, you had to exclude a greater than 80% increase in cardiovascular risk to even be considered for marketing. And after marketing, you’d have to demonstrate cardiovascular safety, specifically no more than a 30% change in cardiovascular risk.
So, this resulted in a large number of so-called cardiovascular outcome trials being performed since then. The first several did as expected. They demonstrated the cardiovascular safety of the drugs. The original studies demonstrated no increased risk of cardiovascular harms and no benefit. The hazard ratio, or the risk of the drug versus placebo, was 1.0. That provided a great deal of reassurance, particularly in the cardiology community. But there were some questions as to why we were prescribing drugs that lowered glucose but didn’t really provide any cardiovascular benefit.
It’s very exciting. About a year ago, there was a presentation of a trial called EMPA-REG, which, for the first time, demonstrated cardiovascular benefit. Until I go to my grave, I’ll remember being in the lecture hall where they pointed out a statistically significant 14% reduction in the first heart attack, stroke, or cardiovascular death, and a 38% reduction in cardiovascular death. The audience was just gob-smacked that a diabetes drug could do that.
These cardiovascular outcome trials in diabetes, in order to accumulate the needed number of cardiovascular events to achieve the possibility of statistical power, have recruited high-risk patients. So, the highest risk patients included in these trials include patients who’ve recently recovered from a hospitalization for acute coronary syndrome. That has been used in a subset of these trials. The next highest risk are patients who haven’t had a recent hospitalization, but have had a prior MI, stroke, or procedure, like bypass surgery or stenting. And then, the next highest risk would be patients who don’t have clinical cardiovascular disease, but have advanced risk factors. So, not only diabetes, but generally some combination of diabetes, age, and let’s say hypertension, with evidence of left ventricular hypertrophy. These patients are higher risk than the general population of patients with type 2 diabetes.
Now that we have had a number of cardiovascular outcome trials that have shown benefit, I think there’s a much greater interest in doing these cardiovascular outcome trials in a way that answers meaningful questions. And so, 2 areas that are still pretty uncertain are: Are there cardiovascular benefits of these newer agents that have demonstrated cardiovascular risk reduction, namely from the SGLT2 inhibitor class and the GLP-1 receptor agonist class? And are there benefits in patients without prior cardiovascular disease and at more moderate risk of cardiovascular events?
To date, the signal has been unclear and, if anything, there doesn’t seem to be benefit, but the number of patients without prior cardiovascular disease has been relatively small. I believe that these drugs will have benefits in those lower risk populations, but we need studies to address that question.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Diabetes Risk Driven by Economic Disparity in Hispanic, Latino Communities
March 28th 2025Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors like education level significantly impact diabetes and hypertension rates, highlighting the need for targeted health interventions across diverse subgroups.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More